These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 1976871)
1. The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. Weide R; Dowding C; Paulsen W; Goldman J Leukemia; 1990 Oct; 4(10):695-9. PubMed ID: 1976871 [TBL] [Abstract][Full Text] [Related]
2. [P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia]. Carulli G; Marini A; Caracciolo F Medicina (Firenze); 1989; 9(4):409-10. PubMed ID: 2576761 [TBL] [Abstract][Full Text] [Related]
3. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. Dhingra K; Talpaz M; Kantarjian H; Ku S; Rothberg J; Gutterman JU; Kurzrock R Leukemia; 1991 Mar; 5(3):191-5. PubMed ID: 2013978 [TBL] [Abstract][Full Text] [Related]
4. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method. Kuwao F; Takahashi I Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617 [TBL] [Abstract][Full Text] [Related]
5. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759 [TBL] [Abstract][Full Text] [Related]
6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related]
7. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976 [TBL] [Abstract][Full Text] [Related]
8. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia. Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536 [TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia]. Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031 [TBL] [Abstract][Full Text] [Related]
10. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia]. Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968 [TBL] [Abstract][Full Text] [Related]
11. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. Hait WN; Choudhury S; Srimatkandada S; Murren JR J Clin Invest; 1993 May; 91(5):2207-15. PubMed ID: 8098047 [TBL] [Abstract][Full Text] [Related]
12. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia. Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222 [TBL] [Abstract][Full Text] [Related]
13. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061 [TBL] [Abstract][Full Text] [Related]
14. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients. Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Michelutti A; Michieli M; Damiani D; Melli C; Geromin A; Russo D; Fanin R; Baccarani M Haematologica; 1994; 79(3):200-4. PubMed ID: 7926967 [TBL] [Abstract][Full Text] [Related]
16. The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. Aumann K; Lassmann S; Schöpflin A; May AM; Wöhrle FU; Zeiser R; Waller CF; Hauschke D; Werner M; Brummer T Hum Pathol; 2011 May; 42(5):719-26. PubMed ID: 21292300 [TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia. Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999 [TBL] [Abstract][Full Text] [Related]
18. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308 [TBL] [Abstract][Full Text] [Related]
19. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927 [TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Zheng C; Li L; Haak M; Brors B; Frank O; Giehl M; Fabarius A; Schatz M; Weisser A; Lorentz C; Gretz N; Hehlmann R; Hochhaus A; Seifarth W Leukemia; 2006 Jun; 20(6):1028-34. PubMed ID: 16617318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]